Related Experiment Video
Updated: Mar 24, 2026

Evaluation of LC3-II Release via Extracellular Vesicles in Relation to the Accumulation of Intracellular LC3-positive Vesicles
Published on: October 18, 2024
The BH3 Mimetic Obatoclax Accumulates in Lysosomes and Causes Their Alkalinization
Vasileios A Stamelos1,2, Natalie Fisher1, Harnoor Bamrah1
1Institute for Science and Technology in Medicine, Keele University, Stoke-on-Trent, Staffordshire, United Kingdom.
Abstract:
Obatoclax belongs to a class of compounds known as BH3 mimetics which function as antagonists of Bcl-2 family apoptosis regulators. It has undergone extensive preclinical and clinical evaluation as a cancer therapeutic. Despite this, it is clear that obatoclax has additional pharmacological effects that contribute to its cytotoxic activity. It has been claimed that obatoclax, either alone or in combination with other molecularly targeted therapeutics, induces an autophagic form of cell death. In addition, obatoclax has been shown to inhibit lysosomal function, but the mechanism of this has not been elucidated. We have evaluated the mechanism of action of obatoclax in eight ovarian cancer cell lines. Consistent with its function as a BH3 mimetic, obatoclax induced apoptosis in three cell lines. However, in the remaining cell lines another form of cell death was evident because caspase activation and PARP cleavage were not observed. Obatoclax also failed to show synergy with carboplatin and paclitaxel, chemotherapeutic agents which we have previously shown to be synergistic with authentic Bcl-2 family antagonists. Obatoclax induced a profound accumulation of LC-3 but knockdown of Atg-5 or beclin had only minor effects on the activity of obatoclax in cell growth assays suggesting that the inhibition of lysosomal function rather than stimulation of autophagy may play a more prominent role in these cells. To evaluate how obatoclax inhibits lysosomal function, confocal microscopy studies were conducted which demonstrated that obatoclax, which contains two basic pyrrole groups, accumulates in lysosomes. Studies using pH sensitive dyes demonstrated that obatoclax induced lysosomal alkalinization. Furthermore, obatoclax was synergistic in cell growth/survival assays with bafilomycin and chloroquine, two other drugs which cause lysosomal alkalinization. These studies explain, for the first time, how obatoclax inhibits lysosomal function and suggest that lysosomal alkalinization contributes to the cytotoxic activity of obatoclax.
Insights
Obatoclax, a BH3 mimetic cancer drug, causes cell death through lysosomal alkalinization, not just apoptosis or autophagy. This mechanism explains its cytotoxic activity in ovarian cancer cells.
Area of Science:
- Oncology
- Cell Biology
- Pharmacology
Background:
- Obatoclax is a BH3 mimetic investigated as a cancer therapeutic.
- Its cytotoxic effects may involve mechanisms beyond apoptosis regulation.
- Previous studies suggested obatoclax induces autophagy and inhibits lysosomal function.
Purpose of the Study:
- To elucidate the mechanism of action of obatoclax in ovarian cancer.
- To investigate the role of autophagy and lysosomal function in obatoclax-induced cell death.
- To determine how obatoclax inhibits lysosomal function.
Main Methods:
- Assessed obatoclax's effect on apoptosis and cell death in eight ovarian cancer cell lines.
- Evaluated obatoclax's synergy with chemotherapeutics.
- Utilized confocal microscopy and pH-sensitive dyes to study lysosomal accumulation and pH changes.
- Investigated the role of autophagy-related proteins (Atg-5, beclin) and lysosomal inhibitors (bafilomycin, chloroquine).
Main Results:
- Obatoclax induced apoptosis in some cell lines but another form of cell death in others.
- Obatoclax did not synergize with carboplatin and paclitaxel.
- Obatoclax accumulated in lysosomes, causing lysosomal alkalinization.
- Lysosomal alkalinization, not autophagy, appeared to be a major contributor to obatoclax's cytotoxicity.
- Obatoclax showed synergy with bafilomycin and chloroquine, which also cause lysosomal alkalinization.
Conclusions:
- Obatoclax exhibits varied cell death mechanisms in ovarian cancer cells.
- Lysosomal alkalinization is a key mechanism by which obatoclax inhibits lysosomal function.
- This lysosomal dysfunction contributes significantly to obatoclax's cytotoxic activity.
Related Concept Videos
Lysosomal Hydrolases
Lysosomes
Lysosomes
Delivery Pathways to the Lysosome
Endocytosis
In endocytosis, the cell membrane takes up macromolecules and particles from the surrounding medium. Clathrin-mediated...
Drug Distribution: Tissue Binding
For...
Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...

